| 1 | netherlands bcell and antibody | | | | | | | 4 | 1.34% |
| 2 | awards and prizes news | | | | | | | 3 | 1.00% |
| 3 | patient advisory board par | | | | | | | 3 | 1.00% |
| 4 | advisory board par awards | | | | | | | 3 | 1.00% |
| 5 | target to b project | | | | | | | 3 | 1.00% |
| 6 | events target to b | | | | | | | 3 | 1.00% |
| 7 | past events target to | | | | | | | 3 | 1.00% |
| 8 | events past events target | | | | | | | 3 | 1.00% |
| 9 | upcoming events past events | | | | | | | 3 | 1.00% |
| 10 | events upcoming events past | | | | | | | 3 | 1.00% |
| 11 | publications events upcoming events | | | | | | | 3 | 1.00% |
| 12 | board par awards and | | | | | | | 3 | 1.00% |
| 13 | par awards and prizes | | | | | | | 3 | 1.00% |
| 14 | clinical partners fundamental partners | | | | | | | 3 | 1.00% |
| 15 | people companies patient advisory | | | | | | | 3 | 1.00% |
| 16 | partners clinical partners fundamental | | | | | | | 3 | 1.00% |
| 17 | us partners clinical partners | | | | | | | 3 | 1.00% |
| 18 | contact us partners clinical | | | | | | | 3 | 1.00% |
| 19 | european network patients news | | | | | | | 3 | 1.00% |
| 20 | about us mission statement | | | | | | | 3 | 1.00% |
| 21 | companies patient advisory board | | | | | | | 3 | 1.00% |
| 22 | 5th european congress of | | | | | | | 2 | 0.67% |
| 23 | european congress of immunology | | | | | | | 2 | 0.67% |
| 24 | network ebc net forum | | | | | | | 2 | 0.67% |
| 25 | cell network ebc net | | | | | | | 2 | 0.67% |
| 26 | european b cell network | | | | | | | 2 | 0.67% |
| 27 | bcell and antibody network | | | | | | | 2 | 0.67% |
| 28 | b cell network ebc | | | | | | | 2 | 0.67% |
| 29 | antibody network about us | | | | | | | 2 | 0.67% |
| 30 | vacancies contact us partners | | | | | | | 2 | 0.67% |
| 31 | and antibody network about | | | | | | | 2 | 0.67% |
| 32 | network about us mission | | | | | | | 2 | 0.67% |
| 33 | news © 2024 netherlands | | | | | | | 1 | 0.33% |
| 34 | macpherson switzerland antibodies set | | | | | | | 1 | 0.33% |
| 35 | switzerland antibodies set boundaries | | | | | | | 1 | 0.33% |
| 36 | antibodies set boundaries limiting | | | | | | | 1 | 0.33% |
| 37 | microbial metabolite penetration and | | | | | | | 1 | 0.33% |
| 38 | metabolite penetration and the | | | | | | | 1 | 0.33% |
| 39 | penetration and the resultant | | | | | | | 1 | 0.33% |
| 40 | and the resultant mammalian | | | | | | | 1 | 0.33% |